{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:25:08Z","timestamp":1762147508273,"version":"build-2065373602"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Human epidermal growth factor receptor 2 (HER2) gene amplification in lung adenocarcinoma is associated with aggressive tumor behavior and poor prognosis. Currently, there is no standard targeted therapy for HER2-amplified lung cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case summary<\/jats:title>\n                    <jats:p>A 60-year-old male presented with a mass in the right cervical spine area. Imaging and pathological examinations confirmed stage IV (T4N3M1) lung adenocarcinoma with metastases to both lungs, multiple lymph nodes, the pleura, the left adrenal gland, and the meninges. Genetic testing revealed HER2 gene amplification and low programmed death-ligand 1 (PD-L1) expression (tumor proportion score &amp;lt;1%). The patient declined conventional chemotherapy due to concerns about side effects. With his informed consent, he was treated with a combination of cadonilimab (a PD-1\/cytotoxic T-lymphocyte antigen 4 bispecific antibody) and disitamab vedotin (an anti-HER2 antibody\u2013drug conjugate), administered intravenously every 3 weeks. After nine treatment cycles over 6 months, imaging assessments showed complete disappearance of the pulmonary lesions, and the achieved complete response (CR) persisted for at least 7 months. The treatment was well-tolerated, and the patient maintained an excellent performance status (Eastern Cooperative Oncology Group score of 0) without significant adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Treatment with cadonilimab and disitamab vedotin induced a sustained complete response in a patient with advanced HER2-amplified lung adenocarcinoma who declined chemotherapy. Thus, this combination therapy may offer a promising, effective, and well-tolerated treatment alternative for similar patients. Further clinical trials are warranted to validate these findings and potentially establish a new standard of care for this subset of lung cancer patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1587210","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:21:33Z","timestamp":1762147293000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Complete response of advanced HER2-amplified lung adenocarcinoma to cadonilimab combined with disitamab vedotin: a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Yue","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keru","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zongying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","article-title":"Lung cancer: current therapies and new targeted treatments","volume":"389","author":"Hirsch","year":"2017","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41571-021-00558-1","article-title":"EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment","volume":"19","author":"Friedlaender","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.14","article-title":"Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy-free, first-line treatment for PD-L1-positive non-small cell lung cancer","volume":"10","author":"Zhou","year":"2020","journal-title":"Clin Transl Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15455","article-title":"The efficacy and safety of a novel PD-1\/CTLA-4 bispecific antibody cadonilimab (AK104) in advanced non-small cell lung cancer: A multicenter retrospective observational study","volume":"15","author":"Li","year":"2024","journal-title":"Thorac Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01614-x","article-title":"Disitamab vedotin: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948","article-title":"N engl J med","volume":"378","author":"Socinski","year":"2018","journal-title":"The New England Journal of Medicine"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100260","article-title":"Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations","volume":"6","author":"Riudavets","year":"2021","journal-title":"ESMO Open"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1230395","article-title":"Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center\u2019s real-world study","volume":"14","author":"Wei","year":"2023","journal-title":"Front Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102415","article-title":"Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial","volume":"68","author":"Wang","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2147\/ott.S349096","article-title":"Efficacy of disitamab vedotin in treating HER2 2+\/FISH- gastric cancer","volume":"15","author":"Dai","year":"2022","journal-title":"OncoTargets Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102351","article-title":"The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives","volume":"104","author":"Patelli","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00584-2","article-title":"Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study","volume":"22","author":"Lakhani","year":"2021","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-018-0011-0","article-title":"A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy","volume":"28","author":"Du","year":"2018","journal-title":"Cell Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.9777","article-title":"Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial","volume":"36","author":"Li","year":"2018","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.10.032","article-title":"A phase II study of trastuzumab emtansine in HER2-positive non-small cell lung cancer","volume":"13","author":"Hotta","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31100471","article-title":"Antibody-drug conjugates for the treatment of non-small cell lung cancer with central nervous system metastases","volume":"31","author":"Bian","year":"2024","journal-title":"Curr Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1587210\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:21:33Z","timestamp":1762147293000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1587210\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":20,"alternative-id":["10.3389\/fonc.2025.1587210"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1587210","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"article-number":"1587210"}}